Hepatitis B Virus
Eisai in-licenses antihepatitis B agent clevudine
Published in Blood Weekly, December 16th, 2004
Under the agreement, Eisai will obtain the exclusive right to develop, manufacture, and market clevudine in 10 Asian countries excluding South Korea. Eisai will develop the compound in those Asian countries, principally in China, aiming at filing of new drug applications for approval.
Clevudine is an antiviral agent for treatment of hepatitis caused by the hepatitis B virus based on DNA polymerase inhibition. In South Korea, Bukwang is currently conducting phase III clinical trials.
For the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-12-16)
More Articles from Blood Weekly
- Cord Blood
IL-15 enhances cytotoxicity/receptor expression/neonatal NK cell expansion - Embryonic Development
Multiple functions of Jab1 required for early embryonic development - HLA Typing
High-resolution class I HLA typing may optimize donor selection/improve outcome - Tissue Engineering
Acellular liver matrix improves survival and function of cultured hepatocytes - Tissue Engineering
Heparin conjugated polylactide may be applied as blood compatible material - Acute Myeloid Leukemia
Dual-specificity fusion toxin selective and potent agent for AML treatment - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
